LAUSR

The purpose of this study is to determine whether magnetic resonance (MR)–proton density fat fraction (PDFF) estimate of negligible hepatic fat percentage (<5%) can exclude significant hepatic steatosis (≥10%) in living liver donor candidates obviating the need for liver biopsy and to perform intraindividual comparisons between MR‐PDFF techniques for hepatic steatosis quantification. In an ethics‐approved retrospective study, 144 liver donor candidates with magnetic resonance spectroscopy (MRS) and 6‐echo Dixon magnetic resonance imaging (MRI) between 2013 and 2015 were included. A subset of 32 candidates underwent liver biopsy. Hepatic fat percentage was determined using MR‐PDFF and histopathology‐determined fat fraction as the reference standard. A receiver operating characteristic analysis with positive predictive value, negative predictive value (NPV), sensitivity, and specificity was performed to discriminate between clinically significant steatosis (≥10%) or not (<10%) at MRS‐PDFF and MRI‐PDFF thresholds of 5% and 10%. Pearson correlation and Bland‐Altman analyses between MRS‐PDFF and MRI‐PDFF were performed for intraindividual comparison of hepatic steatosis estimation. There was significant association between MRS‐PDFF and MRI‐PDFF with HP‐FP. High NPV of 95% (95% confidence interval [CI], 78%‐99%) and 100% (95% CI, 76%‐100%) as well as an area under the curve of 0.90 (95% CI, 0.79‐1.0) and 0.93 (95% CI, 0.84‐1.0) were obtained with a cutoff threshold of 5% MRI‐PDFF and MRS‐PDFF, respectively, to exclude clinically significant steatosis (≥10%). Intraindividual comparison between MRS‐PDFF and MRI‐PDFF showed a Pearson correlation coefficient of 0.83. Bland‐Altman analysis showed a mean difference of 1% with 95% limits of agreement between −1% and 3%. MR‐PDFF estimate of negligible hepatic fat percentage (<5%) has sufficient NPV for excluding clinically significant hepatic steatosis (≥10%) in living liver donor candidates obviating the need for liver biopsy. It may be sufficient to acquire only the multiecho Dixon MRI‐PDFF for hepatic steatosis estimation. Liver Transplantation 24 470–477 2018 AASLD.